Idexx Laboratories Inc
Exchange: NASDAQSector: HealthcareIndustry: Diagnostics & Research
IDEXX Laboratories, Inc., is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500 ® Index. Headquartered in Maine, IDEXX employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries and territories.
Did you know?
Net income compounded at 16.3% annually over 6 years.
Current Price
$569.55
+0.87%GoodMoat Value
$374.04
34.3% overvaluedProfile
Valuation (TTM)
Market Cap$45.48B
P/E42.93
EV$46.96B
P/B28.33
Shares Out79.85M
P/Sales10.57
Revenue$4.30B
EV/EBITDA30.66
Idexx Laboratories Inc (IDXX) Stock Analysis
Market Cap$45.48B
Current Price$569.55
P/E Ratio42.93
Forward P/E—
PEG Ratio2.47
EPS$13.08
Book Value$20.10
P/B Ratio28.33
IDXX Financial Charts
FCF vs CAPEX
FCFCAPEX
Forward estimates use 22.8% FCF growth (CAGR)
Cash vs Debt
Net Debt: 769M
Revenue
2.4B
FY19
2.7B
FY20
3.2B
FY21
3.4B
FY22
3.7B
FY23
3.9B
FY24
4.3B
FY25
Net Income
428M
FY19
582M
FY20
745M
FY21
679M
FY22
845M
FY23
888M
FY24
1.1B
FY25
IDXX 52-Week Range
$361.04
$766.68
50-Day MA: $621.84200-Day MA: $637.14
Did you know?
IDXX's revenue grew at a 10.2% CAGR over the last 6 years.
Idexx Laboratories Inc (IDXX) Financial Summary
Idexx Laboratories Inc (IDXX) is a Healthcare company in the Diagnostics & Research industry, listed on NASDAQ. The stock currently trades at $569.55 with a market capitalization of $45.48B.
Key valuation metrics include a P/E ratio of 42.93, price-to-book ratio of 28.33, and EPS of $13.08. The company reports a profit margin of 24.6% and return on equity of 66.0%.
IDXX Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $45.48B |
| P/E Ratio | 42.93 |
| EPS | $13.08 |
| P/B Ratio | 28.33 |
| P/S Ratio | 10.57 |
| EV/EBITDA | 30.66 |
| Profit Margin | 24.6% |
| Return on Equity | 66.0% |
| Debt/Equity | 0.59 |
IDXX Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $2.41B | $427.72M |
| FY20 | $2.71B | $581.78M |
| FY21 | $3.22B | $744.85M |
| FY22 | $3.37B | $679.09M |
| FY23 | $3.66B | $845.04M |
| FY24 | $3.90B | $887.87M |
| FY25 | $4.30B | $1.06B |
Idexx Laboratories Inc (IDXX) Valuation
Based on GoodMoat's DCF model, Idexx Laboratories Inc has a fair value estimate of $374.04. At the current price of $569.55, the stock appears 52.3% overvalued relative to our intrinsic value estimate.
IDXX Quality Indicators
Idexx Laboratories Inc maintains a profit margin of 24.6% and an operating margin of 31.6%. Return on equity stands at 66.0%. The current ratio is 1.23. Debt-to-equity ratio is 0.59.
About Idexx Laboratories Inc
IDEXX Laboratories, Inc., is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500 ® Index. Headquartered in Maine, IDEXX employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries and territories.
IDXX Free Cash Flow
Idexx Laboratories Inc generated $1.04B in trailing twelve-month free cash flow, representing an FCF yield of 2.29%. This moderate FCF yield indicates reasonable cash generation.
IDXX Shares Outstanding
Idexx Laboratories Inc has 0.08 billion shares outstanding at a share price of $569.55, giving it a market capitalization of $45.48B.
IDXX Recent Insider Trades
Recent insider transactions at Idexx Laboratories Inc include:
| Insider | Type | Shares | Value |
|---|---|---|---|
| Hunt Nimrata (Executive Vice President) | SELL | 1,758 | $1.12M |
| MAZELSKY JONATHAN JAY (President and CEO) | SELL | 1,281 | $833507.63 |
| Hunt Nimrata (Executive Vice President) | SELL | 2,693 | $1.78M |